Saturday, November 18, 2023
The STAL Innovative Biologics Drug Discovery Platform developed by Sanyou stands out as a significant advancement in drug discovery. This cutting-edge platform enables the screening of numerous lead molecules against a common target, surpassing the capabilities of traditional methods. Three key innovations are particularly noteworthy, poised to reshape the drug discovery and development landscape.
Large Molecular Library Capacity: At the core of the STAL platform is its expansive molecular library, surpassing the 10 trillion level. This library integrates nine distinct types of innovative molecular libraries, such as human, human semi-synthetic, human co-light, 2C/4C-type single domains, targeted peptides, targeted small proteins, mouse, rabbit, camel immune monoclonal antibodies, and more. This diverse library forms a robust foundation for the screening and validation of various targets. The STAL platform has demonstrated its effectiveness in facilitating the development of a range of drug molecules, including monoclonal antibody drugs, dual-antibody drugs, ADC drugs, AOC drugs, antibody-nuclein coupled drugs, PDC drugs, CAR-T immune cell therapy, and others.
Full Automation and Integrated R&D: The STAL Trillion-level Innovative Biologics Discovery Platform seamlessly integrates phage display and mammalian cell protein expression technologies. It provides a fully automated screening process and an integrated R&D innovative biologics platform that can be tailored for challenging innovative targets and the development of complex novel molecules.
Future Big Data Integration: Sanyou's STAL Trillion-level Innovative Biologics Discovery Platform and Innovative Biological Drug Integration Platform are designed to be integrated with a big data platform. This integration includes ten key modules offering a flexible range of services, such as a one-stop solution for innovative molecule discovery services, featured technology services, and stage technology services. This initiative aims to support the integration of digitalization, computational biology, and automation to accelerate antibody and peptide discovery and development for research, diagnostics, testing, and therapeutics.
Sanyou's STAL platform represents a significant advance in drug discovery, with its expansive molecular library capacity, full automation, and integration with big data holding the potential to revolutionize the field. This innovation could broaden treatment options and enhance research and development efforts.